[194] reported that a liposomal RNA vaccine encoding melanoma antigens (BNT111), administered in combination with PD-1 blockade, generated strong antigen-specific CD4+ and CD8+ T cell responses with durable activity in patients with checkpoint inhibitor-experienced melanoma. Here, CD8A is linked to melanoma.